Moderna, Biotechnology company

Moderna's COVID-19 vaccine produced by Samsung Biologics will be supplied domestically and globally, allowing Korea to solidify its position as a global COVID-19 vaccine hub.Samsung Biologics will reportedly supply vaccines in Korea first and plans to gradually increase its monthly production to respond to global demand.According to the pharmaceutical and bio industries on the 26th, the Korean government has decided to supply Moderna vaccines produced by Samsung Biologics to Korea and Samsung Biologics has also completed preparations for shipping vaccines.On the 26th, the Korean government announced that it will use 2.435 million doses of Samsung Biologics' Moderna vaccine, which has been approved for emergency use by the Ministry of Food and Drug Safety, for vaccination in Korea. Those vaccines will be available next week.Previously, Samsung Biologics signed a production contract in May this year to take charge of drug products processes such as vial charging and labelling of Moderna's mRNA vaccines and completed test-production of Moderna vaccines in August.Since then, Samsung has been in charge of the main production and has secured sufficient supplies for initial shipments to prepare for domestic and global demand. Under the contract, hundreds of millions of doses of vaccines will be supplied to global markets by 2022.Meanwhile, SK Bioscience has signed a contract with AstraZeneca (AZ) and Novavax to produce COVID-19 vaccines. AZ vaccines produced by SK Bioscience are already being supplied at home and abroad.The Russian Direct Investment Fund (RDIF) has signed a production contract with Hankook Korus consortium and Huons Global consortium for Sputnik V.In addition to the four COVID-19 vaccines signed by the contract, Janssen vaccines are also likely to be produced in Korea. GC Green Cross is currently negotiating with Janssen for the deal, and officials from Janssen visited GC Green Cross's Ochang plant in North Chungcheong Province to complete due diligence last month. There were reportedly no problems in the due diligence process. (ANI/Global Economic)( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

ModernaFOLLOW

Moderna, Latest News

Washington, Jan 7 The efficacy of boosters against Covid-19 will likely decline over time, and people may need ... ...

Washington, Dec 21 American biotechnology company Moderna announced Monday that preliminary data suggests its Covid-19 booster shot appears ... ...

There has been a lot of talk about giving mixed doses of different corona vaccines. However, a research on ... ...

Trevor Noah, host of 'The Daily Show', has touched a nerve among a certain segment of his fans by expressing scepticism in an online post of the motives of Moderna's CEO in pushing for new vaccinations. ...

London, Nov 30 Currently available vaccines for Covid-19 could likely be less effective against the new Omicron variant, ... ...

US-based pharmaceutical company is studying two booster candidates designed to anticipate mutations similar to the Omicron COVID-19 variant. ...

Washington, Nov 1 US drugmaker Moderna has confirmed that the Food and Drug Administration (FDA) has delayed granting ... ...

Moderna's COVID-19 vaccine produced by Samsung Biologics will be supplied domestically and globally, allowing Korea to solidify its position as a global COVID-19 vaccine hub. ...